胃腺癌的表观基因组启动子改变放大基因亚型和免疫原性多样性
该研究分析了110个染色质图谱(H3K4me3、H3K4me1、H3K27ac),涵盖原发胃癌、胃癌细胞系和非恶性胃组织,鉴定出近2000个启动子改变(体细胞启动子),许多在多种上皮恶性肿瘤中失调且常映射至同一基因内的替代启动子,产生潜在促癌亚型(RASA3)。体细胞启动子相关N端肽在肿瘤中相对缺失,具有高亲和力MHC结合预测并在体外引发强效T细胞反应;在多个患者队列中,体细胞启动子使用高的胃癌也显示T细胞溶细胞标志物表达降低。体细胞启动子富集PRC2占据,对EZH2治疗性抑制敏感,并与新癌症相关转录本相关。
要点
- 鉴定出近2000个体细胞启动子改变,常映射至同一基因内替代启动子。
- 体细胞启动子相关N端肽在肿瘤中相对缺失,高亲和力MHC结合并体外引发T细胞反应。
- 体细胞启动子使用高的胃癌队列中T细胞溶细胞标志物表达降低。
核心结论
- 表观基因组启动子改变通过产生肿瘤特异性亚型和降低肿瘤抗原性,可能驱动内在肿瘤发生并帮助新生癌症逃避免疫攻击。
研究设计与样本
- 分析110个染色质图谱(H3K4me3、H3K4me1、H3K27ac),包括原发胃癌、胃癌细胞系和非恶性胃组织。
主要发现
- 鉴定出近2000个启动子改变(体细胞启动子),许多在多种上皮恶性肿瘤中失调且常映射至同一基因内替代启动子,产生潜在促癌亚型(RASA3)。
- 体细胞启动子相关N端肽在肿瘤中相对缺失,具有高亲和力MHC结合预测并在体外引发强效T细胞反应。
- 在多个患者队列中,体细胞启动子使用高的胃癌显示T细胞溶细胞标志物表达降低。
- 体细胞启动子富集PRC2占据,对EZH2治疗性抑制敏感,并与新癌症相关转录本相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Promoter elements play important roles in isoform and cell type-specific expression. We surveyed the epigenomic promoter landscape of gastric adenocarcinoma, analyzing 110 chromatin profiles (H3K4me3, H3K4me1, H3K27ac) of primary gastric cancers, gastric cancer lines, and nonmalignant gastric tissues. We identified nearly 2,000 promoter alterations (somatic promoters), many deregulated in various epithelial malignancies and mapping frequently to alternative promoters within the same gene, generating potential pro-oncogenic isoforms (RASA3). Somatic promoter-associated N-terminal peptides displaying relative depletion in tumors exhibited high-affinity MHC binding predictions and elicited potent T-cell responses in vitro, suggesting a mechanism for reducing tumor antigenicity. In multiple patient cohorts, gastric cancers with high somatic promoter usage also displayed reduced T-cell cytolytic marker expression. Somatic promoters are enriched in PRC2 occupancy, display sensitivity to EZH2 therapeutic inhibition, and are associated with novel cancer-associated transcripts. By generating tumor-specific isoforms and decreasing tumor antigenicity, epigenomic promoter alterations may thus drive intrinsic tumorigenesis and also allow nascent cancers to evade host immunity.Significance: We apply epigenomic profiling to demarcate the promoter landscape of gastric cancer. Many tumor-specific promoters activate different promoters in the same gene, some generating pro-oncogenic isoforms. Tumor-specific promoters also reduce tumor antigenicity by causing relative depletion of immunogenic peptides, contributing to cancer immunoediting and allowing tumors to evade host immune attack. Cancer Discov; 7(6); 630-51. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 539.
引用
- Qamra A, Xing M, Padmanabhan N, et al. Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma. Cancer Discov. 2017. PMID: 28320776. doi:10.1158/2159-8290.CD-16-1022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。